Regeneron Pharmaceuticals Inc (OQ:REGN)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 777 Old Saw Mill River Road
Tel: N/A
IR: See website
Key People
Leonard S. Schleifer
Co-Chairman of the Board, President, Chief Executive Officer, Founder
George D. Yancopoulos
Co-Chairman of the Board, President, Chief Scientific Officer
Christopher R. Fenimore
Chief Financial Officer, Senior Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Marion E. McCourt
Executive Vice President - Commercial
Andrew J. Murphy
Executive Vice President - Research
Neil Stahl
Executive Vice President - Research and Development
Jason Pitofsky
Vice President, Controller
Business Overview
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Financial Overview
For the three months ended 31 March 2024, Regeneron Pharmaceuticals Inc revenues decreased 1% to $3.15B. Net income decreased 12% to $722M. Revenues reflect EYLEA segment decrease of 16% to $1.2B, Roche segment decrease of 100% to $500K. Net income also reflects Research and development increase of 26% to $706.5M (expense), selling increase of 15% to $602.8M (expense).
Employees: 13,450 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $106,679M as of Mar 31, 2024
Annual revenue (TTM): $13,100M as of Mar 31, 2024
EBITDA (TTM): $4,440M as of Mar 31, 2024
Net annual income (TTM): $3,858M as of Mar 31, 2024
Free cash flow (TTM): $3,930M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 110,185,503 as of Apr 16, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.